Illumina Told To Pay $334M In DNA Sequencing Patent Trial
A Delaware federal jury decided Friday that Illumina willfully infringed two Complete Genomics Inc. DNA sequencing patents and should pay $334 million in damages, while also invalidating three Illumina patents that...To view the full article, register now.
Already a subscriber? Click here to view full article